SCHEMBL7516493

SCHEMBL7516493

CCOC(=O)CC1Cc2ccc(O)cc2Cc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 6/20 0.45
MTNR1B P49286 6/20 0.45
HTR2A P28223 1/20 0.45
HSD17B1 P14061 1/20 0.43
ITGB3 P05106 4/20 0.42
ITGAV P06756 4/20 0.42
ITGB1 P05556 1/20 0.42
ITGA2B P08514 1/20 0.42
ITGB5 P18084 1/20 0.42
CYP1A2 P05177 1/20 0.39
MIF P14174 1/20 0.39
DRD2 P14416 2/20 0.39
DRD1 P21728 2/20 0.39
DRD5 P21918 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6857764 1.00 MTNR1A (0.45) MTNR1AMTNR1BHTR2AHSD17B1ITGB3
SCHEMBL6857996 1.00 MTNR1A (0.45) MTNR1AMTNR1BHTR2AHSD17B1ITGB3
SCHEMBL19984866 0.84 CYP1A2 (0.49) MTNR1AMTNR1BCYP1A2
SCHEMBL6643325 0.83 ITGB3 (0.53) MTNR1AMTNR1BHTR2AITGB3ITGAV
SCHEMBL6642395 0.83 ITGB3 (0.53) MTNR1AMTNR1BHTR2AITGB3ITGAV
SCHEMBL6646029 0.83 ITGB3 (0.53) MTNR1AMTNR1BHTR2AITGB3ITGAV
SCHEMBL6862777 0.82 MTNR1A (0.40) MTNR1AMTNR1BHSD17B1ITGB3ITGAV
SCHEMBL6862775 0.82 MTNR1A (0.40) MTNR1AMTNR1BHSD17B1ITGB3ITGAV
SCHEMBL7442839 0.82 SRD5A2 (0.44) MTNR1AMTNR1BITGB3ITGAVITGB1
SCHEMBL6857908 0.81 MTNR1A (0.38) MTNR1AMTNR1BITGB3ITGAVITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020032187-A1 Method for stimulating bone formation SMITHKLINE BEECHAM CORPORATION 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032187-A1 Method for stimulating bone formation BMP2, BMP4, SOST MTNR1A 603/4885MTNR1B 395/4885HTR2A 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.